Novavax Inc. (NVAX) – Get the report shares jumped higher on Friday after the drugmaker kicked off the final stages of its coronavirus vaccine development programs in the UK.
Novavax said the trial will recruit around 10,000,000 volunteers aged 18 to 84 – at least a quarter of whom are over 65 – over the next four to six weeks to test the effectiveness and the immunogenicity of its candidate vaccine against the coronavirus NVX-CoV2373.
Novavax also said it was increasing its production capacity, aiming to produce around 2 billion doses each year if the current vaccine candidate were to meet regulatory approval.
“With a high level of transmission of SARS-CoV-2 observed and expected to continue in the UK, we are optimistic that this pivotal Phase 3 clinical trial will register quickly and provide a short-term view of the efficacy of NVX-CoV2373, ”said Novavax. Gregory Glenn, President of R&D. “The data from this trial should support regulatory submissions for registration in the UK, EU and other countries. We are grateful for the support of the UK government, including its Department of Health and Social Affairs and the National Institute for Health Research, to advance this important research. “
Novavax shares were marked 11.1% higher early in Friday trading to change hands at $ 113.90 each, a move that would extend the stock’s three-month gain to around 27.1%.
Earlier this week, Johnson & Johnson (JNJ) – Get the report kicked off the final cycle of its own vaccine trial, announcing that the single dose, which will be tested on 60,000 trial participants, follows positive data from a Phase 2 trial, which demonstrated that “the profile safety and immunogenicity after a single vaccination were supporting further development. “
The World Health Organization says about 150 potential vaccines are currently under some form of study, with 34 active human trials underway from Russia to Bahrain.
Several American companies are also in the hunt, including Moderna (RNAm) – Get the report, Novavax and Pfizer (PFE) – Get the report, who said earlier this month that he was considering regulatory approval for this mRNA-based vaccine as early as October.
Eli Lilly & Co (THERE IS) – Get the report , meanwhile, reached an agreement with Amgen (AMGN) – Get the report last week to manufacture its potential antibody treatment against the coronavirus as global cases appear poised to pass the 30 million mark.
Eli Lilly said he was studying several neutralizing antibiotics for the prevention and treatment of COVID-19, either in combination with other drugs or as a so-called monotherapy, adding that his collaboration with Amgen “would significantly increase the supply capacity “of any potential treatment. breakthrough.